The study is a multi-center, observational study to evaluate the feasibility of α-synuclein-related biomarkers and imaging data in the disease diagnosis and prognosis evaluation in Synucleinopathies and healthy subjects.
In the study, a total number of no more than 100 subjects are planned to be enrolled. Subjects who are eligible for enrollment will be enrolled in the study after signing the informed consent form (ICF) and undergo 3 visits, including the baseline visit (the day of first blood sample collection), visit 1 (day 183 post-enrollment), and visit 2 (day 366 post-enrollment).
Study Type
OBSERVATIONAL
Enrollment
89
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Nanjing Brain Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
To evaluate the difference of α-synuclein-related biomarkers between patients and healthy subjects
Time frame: 12 months
Attempt to evaluate the correlation between α-synuclein and disease progression by comparing α-synuclein levels at baseline
Time frame: 6 months, and 12 months
To evaluate the differences of imaging-related indicators in PD, MSA, and their correlation with the disease by brain positron emission tomography (PET)
Time frame: 12 months
To evaluate the correlation between α-synuclein levels and imaging data.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.